3 Health Care Stocks Dragging The Sector Down
All three major indices are trading down today with the
Dow Jones Industrial Average
(
^DJI
) trading down 29 points (-0.2%) at 17,702 as of Tuesday, Nov. 10, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,315 issues advancing vs. 1,646 declining with 122 unchanged.
The Health Care sector currently sits down 0.8% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the sector include
(
), down 11.8%,
(
), down 11.0%,
Valeant Pharmaceuticals International
(
), down 7.1%,
(
), down 4.1% and
(
), down 3.7%. Top gainers within the sector include
(
), up 1.2%,
(
), up 1.2%,
(
), up 0.9%,
(
), up 0.8% and
(
), up 0.7%.
TheStreet would like to highlight 3 stocks pushing the sector lower today:
3.
(
) is one of the companies pushing the Health Care sector lower today. As of noon trading, Mallinckrodt is down $3.47 (-6.0%) to $54.54 on heavy volume. Thus far, 3.6 million shares of Mallinckrodt exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $54.17-$59.48 after having opened the day at $57.66 as compared to the previous trading day's close of $58.01.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. Mallinckrodt has a market cap of $8.2 billion and is part of the drugs industry. Shares are down 41.4% year-to-date as of the close of trading on Monday. Currently there are 9 analysts that rate Mallinckrodt a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Mallinckrodt
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is down $0.34 (-0.8%) to $40.62 on light volume. Thus far, 1.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $40.59-$40.84 after having opened the day at $40.82 as compared to the previous trading day's close of $40.96.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $101.4 billion and is part of the drugs industry. Shares are down 2.8% year-to-date as of the close of trading on Monday. Currently there are 3 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.
TheStreet Ratings rates
GlaxoSmithKline
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full
GlaxoSmithKline Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is down $0.83 (-0.9%) to $87.70 on average volume. Thus far, 704,171 shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $87.64-$88.20 after having opened the day at $87.74 as compared to the previous trading day's close of $88.53.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis has a market cap of $214.7 billion and is part of the drugs industry. Shares are down 4.5% year-to-date as of the close of trading on Monday. Currently there are 6 analysts that rate Novartis a buy, 1 analyst rates it a sell, and 1 rates it a hold.
TheStreet Ratings rates
Novartis
as a
. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider
Health Care Select Sector SPDR
(
) while those bearish on the health care sector could consider
ProShares Ultra Short Health Care
(
).